Dasatinib Dose Optimization With Weekend Drug Holiday for Improved Tolerability in Chronic Myeloid Leukemia (DasaHIT): A German Chronic Myeloid Leukemia Alliance Randomized Trial
Journal of Clinical Oncology · 13.11.2026
DOI: 10.1200/jco-26-00899 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, online erschienen am 13.11.2026. Verfasst von Paul La Rosée und 19 weiteren Autor:innen. Beteiligte Einrichtung: Klinik für Innere Medizin II, Schwarzwald-Baar-Klinikum, Villingen-Schwenningen, Germany. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
PURPOSE To compare standard-dose dasatinib 100 mg once daily with reduced-dose using a weekend drug holiday to improve tolerability for patients with chronic myeloid leukemia (CML). PATIENTS AND METHODS Patients with chronic phase CML (CP-CML) were randomly assigned to either receive standard-of-care dasatinib 100 mg once daily or an intermittent dasatinib schedule (5 days on, 2 days [weekend] off) in a prospective multicenter phase III trial. Achievement of major molecular remission (MMR) at 24 months and a newly developed cumulative toxicity score were coprimary end points. RESULTS Of 289 eligible patients, 147 were assigned to standard-of-care dasatinib and 142 to intermittent dosing. Eighty percent of patients received first-line treatment (n = 232). In the standard arm, 105 of 130 patients (81% [95% CI, 74% to 88%) achieved MMR at 24 months compared with 101 of 130 patients (78% [95% CI, 71% to 85%]) in the experimental arm resulting in noninferiority within the prespecified noninferiority margin of 15% ( P = .009). Among second- or later-line patients, MMR at 24 months was 24% lower, failing noninferiority. Comparison of grade 2-4 toxicities revealed no significant difference between the treatment arms. However, a post hoc analysis of toxicities of special interest (pleural effusion/pericardial effusion) showed 21 of 130 patients (16%) in the standard arm versus 10 of 125 (8%) patients in the experimental arm ( P = .0464). Consistently, health-related quality of life improved mainly in first-line patients, with more favorable outcomes in the experimental arm. CONCLUSION Intermittent dasatinib dosing with weekend treatment holidays in patients with CP-CML is noninferior to continuous dosing with respect to MMR at 24 months, at least in the first-line setting. The incidence of pleural or pericardial effusion appears to be reduced compared with standard-of-care continuous dosing.
Autor:innen und Institutionen
- Klinik für Innere Medizin II, Schwarzwald-Baar-Klinikum, Villingen-Schwenningen, Germany.
- Klinik für Innere Medizin II, Universitätsklinikum Jena, Comprehensive Cancer Center Central Germany, Campus Jena, Jena, Germany.
- Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule Hannover, Hannover, Germany.
- Universitätsklinik für Innere Medizin V, Hämatologie und Onkologie, Comprehensive Cancer Center Innsbruck (CCCI) and Tiroler Krebsforschungsinstitut (TKFI), Medizinische Universität Innsbruck, Innsbruck, Austria.
- Universitätsklinikum Bonn, Centrum für Integrierte Onkologie Aachen, Bonn, Köln, Düsseldorf (CIO ABCD), Bonn, Germany.
- MVZ Mariahilfbergweg, Amberg, Germany.
ORCID-Profile: Philipp Ernst, Dominik Wolf, Lino L Teichmann, Susanne Saussele, Cornelius F Waller, Tim H Brümmendorf, Andreas Burchert, Jenny Rinke, Ali Albeer, Thomas Ernst, Markus Pfirrmann, Andreas Hochhaus
Zitieren
APA
La Rosée, P., Ernst, P., Fabisch, C., Brioli, A., Wolf, D., Teichmann, L. L., Fischer von Weikersthal, L., Saussele, S., Früh, T., Stegelmann, F., Waller, C. F., Hertenstein, B., Brümmendorf, T. H., Burchert, A., Rinke, J., Albeer, A., Ernst, T., Pfirrmann, M., Hochhaus, A., & German CML Study Group (2026). Dasatinib Dose Optimization With Weekend Drug Holiday for Improved Tolerability in Chronic Myeloid Leukemia (DasaHIT): A German Chronic Myeloid Leukemia Alliance Randomized Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-00899
Vancouver
La Rosée P, Ernst P, Fabisch C, Brioli A, Wolf D, Teichmann LL, et al. Dasatinib Dose Optimization With Weekend Drug Holiday for Improved Tolerability in Chronic Myeloid Leukemia (DasaHIT): A German Chronic Myeloid Leukemia Alliance Randomized Trial. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-00899
BibTeX
@article{LaRose2026,
author = {La Rosée, Paul and Ernst, Philipp and Fabisch, Christian and Brioli, Annamaria and Wolf, Dominik and Teichmann, Lino L and Fischer von Weikersthal, Ludwig and Saussele, Susanne and Früh, Theresa and Stegelmann, Frank and Waller, Cornelius F and Hertenstein, Bernd and Brümmendorf, Tim H and Burchert, Andreas and Rinke, Jenny and Albeer, Ali and Ernst, Thomas and Pfirrmann, Markus and Hochhaus, Andreas and German CML Study Group, German CML Study Group},
title = {Dasatinib Dose Optimization With Weekend Drug Holiday for Improved Tolerability in Chronic Myeloid Leukemia (DasaHIT): A German Chronic Myeloid Leukemia Alliance Randomized Trial},
journal = {Journal of Clinical Oncology},
year = {2026},
doi = {10.1200/jco-26-00899}
}
EUVIMED